Top

Langenbeck's Archives of Surgery

Published in:

01-01-2013 | Original Article

Cinacalcet effects on the perioperative course of patients with secondary hyperparathyroidism

Authors: Denis Wirowski, Peter E. Goretzki, Katharina Schwarz, Bernhard J. Lammers

Published in: Langenbeck's Archives of Surgery | Issue 1/2013

Abstract

Purpose

Since its registration in 2004, the calcimimetic agent cinacalcet has been established as an alternative treatment for secondary hyperparathyroidism (SHPT). Working by allosteric activation of the calcium-sensing receptor, cinacalcet can lower parathyroid hormone (PTH) and calcium (Ca) in patients with SHPT. The influence of calcimimetics on the perioperative course has been unclear so far.

Methods

We retrospectively analyzed the data of patients with primary operation for SHPT between 2004 and 2011, comparing the perioperative course of patients with and without preoperative cinacalcet treatment.

Results

Fifty-six patients had cinacalcet therapy, and 54 patients had no calcimimetic medication prior to surgery. Gender, age, hemodialysis, and medical treatment were similar in both groups. Also, PTH levels were similar preoperatively and postoperatively (preoperative, 1,249 ± 676 vs. 1,196 ± 601 pg/ml; postoperative, 86 ± 220 vs. 62 ± 91 pg/ml). Patients with cinacalcet preoperatively had significant lower Ca levels preoperatively (2.49 ± 0.25 vs. 2.61 ± 0.24 mmol/l) and postoperatively (1.75 ± 0.37 vs. 1.86 ± 0.35 mmol/l) and had a higher rate of oral Ca substitution postoperatively (93 vs. 74 %). The risk for postoperative persistent disease was slightly higher in these patients compared to those without preoperative cinacalcet therapy (5 vs. 0 %, not significant).

Conclusions

In our experience, cinacalcet did not alter the perioperative course in SHPT patients.

Messa P, Alfieri C, Brezzi B (2008) Cinacalcet: pharmacological and clinical aspects. Expert Opin Drug Metab Toxicol 4:1551–1560. doi:10.1517/17425250802587017 PubMedCrossRef

Block GA, Martin KJ, de Francisco ALM, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516–1525PubMedCrossRef

Bover J, Pérez R, Molina M, Benavides B, Ariza F, Miguel JL, Tornero F, Torregrosa JV (2010) Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients: an observational study in routine clinical practice. Nephron Clin Pract 118:c109–c121. doi:10.1159/000319882 PubMedCrossRef

de Francisco ALM (2008) New strategies for the treatment of hyperparathyroidism incorporating calcimimetics. Expert Opin Pharmacother 9:795–811. doi:10.1517/14656566.9.5.795 PubMedCrossRef

Dotzenrath C (2010) Indications for parathyroidectomy in renal hyperparathyroidism. Comments on the significance of new therapeutics. Chirurg 81:902–908. doi:10.1007/s00104-010-1968-5 PubMedCrossRef

Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A (2012) Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease. Int Urol Nephrol 44:541–547. doi:10.1007/s11255-010-9897-2 PubMedCrossRef

Smith DH, Johnson ES, Thorp ML, Yang X, Neil N (2009) Hyperparathyroidism in chronic kidney disease: a retrospective cohort study of costs and outcome. J Bone Miner Metab 27:287–294. doi:10.1007/s00774-009-0048-8 PubMedCrossRef

Strippoli GFM, Tong A, Palmer SC, Elder GJ, Craig JC (2006) Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 18:CD006254. doi:10.1002/14651858.CD006254

Costa-Hong V, Jorgetti V, Gowdak LHW, Moyses RMA, Krieger EM, De Lima JJG (2007) Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery 142:699–703. doi:10.1016/j.surg.2007.06.015 PubMedCrossRef

10.

Elder GJ (2005) Parathyroidectomy in the calcimimetic era. Nephrology (Carlton) 10:511–515. doi:10.1111/j.1440-1797.2005.00476.x CrossRef

11.

Lorenz K, Sekulla C, Dralle H (2011) Surgical management of renal hyperparathyroidism. Zentralbl Chir. doi:10.1055/s-0030-1262542

12.

Schlosser K, Schmitt CP, Bartholomaeus JE, Suchan KL, Buchler MW, Rothmund M, Weber T (2008) Parathyroidectomy for renal hyperparathyroidism in children and adolescents. World J Surg 32:801–806. doi:10.1007/s00268-007-9318-6 PubMedCrossRef

13.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). Kidney Int 113:S1–S130. doi:10.1038/ki.2009.188(-197)

14.

National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3):S1–S201. doi:10.1016/S0272-6386(03)00905-3

15.

Amgen Inc. (2004–2011) Sensipar® (cinacalcet) tablets. Full prescribing information. Available at http://pi.amgen.com/united_states/sensipar/sensipar_pi_hcp_english.pdf. Accessed 31 Oct 2011

16.

Reichel H, Braun J (2011) German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY). Dtsch Med Wochenschr 136:123–128. doi:10.1055/s-0030-1247876 PubMedCrossRef

17.

Messa P, Alfieri C, Brezzi B (2011) Clinical utilization of cinacalcet in hypercalcemic conditions. Expert Opin Drug Metab Toxicol 7:517–528. doi:10.1517/17425255.2011.562196 PubMedCrossRef

18.

Frazão JM, Messa P, Mellotte GJ, Geiger H, Hagen EC, Quarles LD, Kerr PG, Baños A, Dehmel B, Urena P (2011) Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. Clin Nephrol 76:233–243. doi:10.5414/CN106965 PubMed

19.

Ureña P, Jacobson SH, Zitt E, Vervloet M, Malberti F, Ashman N, Leavey S, Rix M, Os I, Sha H, Ryba M, Bencova V, Baños A, Zani V, Fouque D (2009) Cinacalcet and achievement of the NKF/K-DOQI™ recommended target values for bone and mineral metabolism in real-world clinical practice—the ECHO observational study. Nephrol Dial Transplant 24:2852–2859. doi:10.1093/ndt/gfp144 PubMedCrossRef

20.

Dillon ML, Frazee LA (2011) Cinacalcet for the treatment of primary hyperparathyroidism. Am J Ther 18:313–322. doi:10.1097/MJT.0b013e3181bdc3d0 PubMedCrossRef

21.

Duntas LH, Stathatos N (2011) Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects. Endocrine 39:199–204. doi:10.1007/s12020-011-9452-7 PubMedCrossRef

22.

Khan A, Grey A, Shoback D (2009) Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 94:373–381. doi:10.1210/jc.2008-1762 PubMedCrossRef

23.

Sajid-Crockett S, Singer FR, Hershman JM (2008) Cinacalcet for the treatment of primary hyperparathyroidism. Metabolism 57:517–521. doi:10.1016/j.metabol.2007.11.014 PubMedCrossRef

24.

Wüthrich RP, Martin D, Bilezikian JP (2007) The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 37:915–922. doi:10.1111/j.1365-2362.2007.01874.x PubMedCrossRef

25.

Moyes VJ, Monson JP, Chew SL, Akker SA (2010) Clinical use of cinacalcet in MEN1 hyperparathyroidism. Int J Endocrinol. doi:10.1155/2010/906163

26.

Cunningham J, Danese M, Olson K, Klassen P, Chertow GM (2005) Effects of the calcimimetic cinacalcet HCL on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793–1800. doi:10.1111/j.1523-1755.2005.00596.x PubMedCrossRef

27.

Taniguchi M, Yamada S, Tokumoto M, Tsuruya K, Hirakata H, Fujimi S, Iida M (2009) Does cinacalcet improve the prognosis of dialysis patients? Ther Apher Dial 13(Suppl 1):S15–S19. doi:10.1111/j.1744-9987.2009.00770.x PubMedCrossRef

28.

Schlosser K, Zielke A, Rothmund M (2004) Medical and surgical treatment for secondary and tertiary hyperparathyroidism. Scand J Surg 93:288–297PubMed

29.

Schneider R, Bartsch DK, Schlosser K (2011) Hat sich das preoperative Erscheinungsbild vor Parathyreoidektomien bei Patienten mit sekundärem Hyperparathyreoidismus im Zeitverlauf und durch neue medikamentöse Therapieoptionen verändert? Abstract, 128th Congress of the German Society of Surgery 2011, Munich, Germany

30.

Meyers MO, Russell CP, Ollila DW, Yeh JJ, Kim HJ, Calvo BF (2009) Postoperative hypocalcemia after parathyroidectomy for renal hyperparathyroidism in the era of cinacalcet. Am Surg 75:843–847PubMed

31.

Ghani A, Baxter P (2011) Surgical parathyroidectomy versus cinacalcet therapy: in the management of secondary hyperparathyroidism. Otolaryngol Head Neck Surg. doi:10.1177/0194599811428272

32.

Moe SM, Cunningham J, Bommer J, Adler S, Rosansky SJ, Urena-Torres P, Albizem MB, Guo MD, Zani VJ, Goodman WG, Sprague SM (2005) Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 20:2186–2193. doi:10.1093/ndt/gfh966 PubMedCrossRef

33.

Hirai T, Nakashima A, Takasugi N, Yorioka N (2010) Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients. Ther Apher Dial 14:577–582. doi:10.1111/j.1744-9987.2010.00843.x PubMedCrossRef

34.

Hirai T, Nakashima A, Takasugi N, Yorioka N (2010) Response of secondary hyperparathyroidism to cinacalcet depends on parathyroid size. Nephron Clin Pract 114:c187–c193. doi:10.1159/000262301 PubMedCrossRef

35.

Tominaga Y, Matsuoka S, Uno N, Sato T (2008) Parathyroidectomy for secondary hyperparathyroidism in the era of calcimimetics. Ther Apher Dial 12(Suppl 1):S21–S26. doi:10.1111/j.1744-9987.2008.00627.x PubMedCrossRef

36.

Miller G, Davis J, Shatzen E, Colloton M, Martin D, Henley CM (2012) Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD. Nephrol Dial Transplant 27:2198–2205. doi:10.1093/ndt/gfr589 PubMedCrossRef

37.

Kakuta T, Tanaka R, Kanai G, Sawaya A, Hirukawa T, Sato A, Saito A (2009) Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism? Ther Apher Dial 13(1):S20–S27. doi:10.1111/j.1744-9987.2009.00772.x PubMedCrossRef

38.

Narayan R, Perkins RM, Berbano EP, Yuan CM, Neff RT, Sawyers ES, Yeo FE, Vidal-Trecan GM, Abbott KC (2007) Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 49:801–813. doi:10.1053/j.ajkd.2007.03.009 PubMedCrossRef

39.

Schneider R, Kolios G, Koch BM, Fernández ED, Bartsch DK, Schlosser K (2010) An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism—the German perspective. Surgery 148:1091–1099. doi:10.1016/j.surg.2010.09.009 PubMedCrossRef

Title: Cinacalcet effects on the perioperative course of patients with secondary hyperparathyroidism
Authors: Denis Wirowski
Peter E. Goretzki
Katharina Schwarz
Bernhard J. Lammers
Publication date: 01-01-2013
Publisher: Springer-Verlag
Published in: Langenbeck's Archives of Surgery / Issue 1/2013
Print ISSN: 1435-2443
Electronic ISSN: 1435-2451
DOI: https://doi.org/10.1007/s00423-012-1005-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cinacalcet effects on the perioperative course of patients with secondary hyperparathyroidism

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2013

Surgical management of Crohn’s disease

Single institution’s experience in laparoscopic appendectomy as a suitable therapy for complicated appendicitis

Evaluation of sexual function in sexually active women 1 year after transvaginal NOTES: a prospective cohort study of 106 patients

Transplantation with hyper-reduced liver grafts in children under 10 kg of weight

Fast-track surgery: procedure-specific aspects and future direction

Necrotizing fasciitis: is the bacterial spectrum changing?